Worth reading
38Recurring
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
124
¥ million (amount of operating loss expansion)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationInterim accounting period of the fiscal year ending September 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥253 million
Operating profit¥-584 million operating loss
Ordinary income¥-560 million ordinary loss
Net income¥-603 million net loss
Selling, general and administrative expenses¥666 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue¥35 million
- Increase in gross profit¥30 million
- Increase in Selling, General and Administrative Expenses¥154 million
- Decrease in non-operating income¥-3 million
- Increase in extraordinary losses¥1 million
New initiatives
- Launched 4 new hit compound discovery programs
- Launched new drug discovery concepts targeting large existing markets, including kinase inhibitors
- Entered into a joint research agreement with Talus Bioscience
- Entered into a drug discovery partnership agreement with Receptor AI
- Initiated the PPI drug discovery consortium initiative
Key KPIsA metric the company considers important as a management benchmark.
- Annual target for the number of HTS programs10 Program
- Number of hit compounds obtained2 Compounds
- Overall response rate for E738636.7 %
- Overall response rate for E7386 in patients with no prior treatment with LENVIMA57.1 %
- Number of protein-protein interactions involved in PPI650,000 Type
- Number of kinases500 More than [number] types
Market Size / Share
- PPI-related marketFigures16
- Kinase marketFigures476
- 2030 forecast for the kinase marketFigures8
- Number of approved kinase productsFigures70
- Membrane protein-related marketFiguresSeveral hundred billion
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Interim accounting period of the fiscal year ending September 2026 |
| Net Sales | ¥253 million |
| Operating profit | ¥-584 million (operating loss) |
| Ordinary income | ¥-560 million (ordinary loss) |
| Net income | ¥-603 million (net loss) |
| Selling, general and administrative expenses | ¥666 million |
| Breakdown of Factors Affecting the Change | Factors Increase in revenue / Amount ¥35 million, Factors Increase in gross profit / Amount ¥30 million, Factors Increase in Selling, General and Administrative Expenses / Amount ¥154 million, Factors Decrease in non-operating income / Amount ¥-3 million, Factors Increase in extraordinary losses / Amount ¥1 million |
| Key KPIs | Indicator name Annual target for the number of HTS programs / Value 10 Program, Indicator name Number of hit compounds obtained / Value 2 Compounds, Indicator name Overall response rate for E7386 / Value 36.7 %, Indicator name Overall response rate for E7386 in patients with no prior treatment with LENVIMA / Value 57.1 %, Indicator name Number of protein-protein interactions involved in PPI / Value 650,000 Type, Indicator name Number of kinases / Value 500 More than [number] types |
| Market Size / Share | Subject PPI-related market / Figures 16 US$100 million (2023), Subject Kinase market / Figures 476 US$100 million (2020), Subject 2030 forecast for the kinase market / Figures ¥8 trillion, Subject Number of approved kinase products / Figures 70 More than [number] products, Subject Membrane protein-related market / Figures Several hundred billion |
| New initiatives | Launched 4 new hit compound discovery programs, Launched new drug discovery concepts targeting large existing markets, including kinase inhibitors, Entered into a joint research agreement with Talus Bioscience, Entered into a drug discovery partnership agreement with Receptor AI, Initiated the PPI drug discovery consortium initiative |
Items this document does not state (20)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company's income statement shows that gross profit increased by ¥30 million, while selling, general and administrative expenses increased by ¥154 million. No other specific explanation is provided for the widening operating loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.